Denosumab
Denosumab is a fully human antibody that blocks a signal called RANKL. RANKL is the cytokine that bone-dissolving cells (osteoclasts) need to form, activate, and survive. By blocking the RANK-RANKL system, denosumab strongly suppresses bone breakdown. It is FDA-approved for osteoporosis in high-fracture-risk postmenopausal women and men. (That product is Prolia, 60 mg under the skin every 6 months.) It is also approved to prevent bone complications when cancer spreads to bone (as Xgeva, a higher dose). And it treats giant cell tumor of bone. Unlike bisphosphonates, RANKL blockade also touches immune cells and tumor environments. That is because RANKL sits on osteoblasts, activated T cells, and stromal cells beyond bone. So researchers are exploring cancer and immune uses. Observational data hint at lower heart and overall death rates in treated patients, beyond fracture prevention. That echoes bisphosphonate findings, but confounding and frailty bias muddy it. One critical safety point. If you stop denosumab without switching to a bisphosphonate, bone loss rebounds sharply. Rare jawbone osteonecrosis and atypical thigh fractures are also reported.
Last reviewed:
This definition is educational and is not medical advice, a diagnosis, or treatment. Talk to a doctor about any health decisions. Read our full medical disclaimer